On Tuesday, Vericel received an upgrade to its Relative Strength (RS) Rating, from 79 to 84.
IBD's proprietary RS Rating identifies market leadership by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Over 100 years of market history shows that the market's biggest winners typically have an RS Rating of above 80 as they launch their biggest price moves.
Risk Management In The Stock Market: How Much Money To Invest Now
Vericel is now considered extended and out of buy range after clearing a 50.00 buy point in a first-stage double bottom. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company posted 0% EPS growth in the latest quarterly report, while sales growth came in at 27%.
Vericel earns the No. 31 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
